All haematology articles
-
NewsLilly adds potential first-in-class Type II JAK2 inhibitor to haematology portfolio
The pharmaceutical company’s $2.3 billion acquisition of Ajax Therapeutics set to advance outcomes for myeloproliferative neoplasms.
-
NewsMerck expands haematology pipeline with $6.7bn acquisition of Terns Pharmaceuticals
Deal strengthens Merck’s oncology portfolio with addition of a potential best-in-class oral TKI for chronic myeloid leukaemia.
-
NewsT-cell engagers set to drive immuno-oncology market
Amid intensifying market competition, the next-generation therapies could shape the future of oncology.